Clinical Trials
39 trialsEvaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
FLAMINGO-01
Greenwich LifeSciences, Inc.
NeckTAR-IN
Centre Jean Perrin
CASSIOPEIA
Novartis
ALPHA3
Allogene Therapeutics
FIL_GAZEBO
Fondazione Italiana Linfomi - ETS
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
M.D. Anderson Cancer Center
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Amgen
Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)
M.D. Anderson Cancer Center
K4CARE-PDAC
Chang Gung Memorial Hospital
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
Amgen
HER2 CR
Nagoya City University
ROTATE
Yale University
MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma
University of Nebraska
SHERLOCK
University Health Network, Toronto
PREeMPT
Medical College of Wisconsin
retroESGO ov1
European Society of Gynaecological Oncology
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Dana-Farber Cancer Institute
GUIDE.MRD-01-CRC: Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Colorectal Cancer
University of Aarhus
Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL
Weill Medical College of Cornell University
PREDICT-RD
UNC Lineberger Comprehensive Cancer Center
A Study of Tetrathiomolybdate (TM) Plus Capecitabine
Dartmouth-Hitchcock Medical Center
VEN+IDAC vs IDAC in AML
Guangdong Second Provincial General Hospital
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Roswell Park Cancer Institute
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
Stanford University
RT4
The Lymphoma Academic Research Organisation
PALAVY
Abramson Cancer Center at Penn Medicine
Motixafortide for MRD Sensitization in AML
Washington University School of Medicine
ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma
Ruijin Hospital
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Masonic Cancer Center, University of Minnesota
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Eastern Cooperative Oncology Group
DEL-MRD-CHID
Fudan University
ctDNA in Cutaneous Squamous Cell Carcinoma
Massachusetts Eye and Ear Infirmary
AlloNK1
Singapore General Hospital
Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML
Peking University People's Hospital
CIRCALL
Assistance Publique - Hôpitaux de Paris
Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome
City of Hope Medical Center
EMAT
Medical College of Wisconsin